Filing Flows › Halozyme Therapeutics (HALO) › Guidance history
Halozyme Therapeutics (HALO) guidance history: what it guided and what it reported
Halozyme Therapeutics gave guidance in 12 earnings releases on file since Aug 6, 2024. Of 3 guided periods since reported, it met or beat its own guidance 3 times (100%). Revenue: 3 of 3, on average +19.4% against the guided midpoint. Its releases raised guidance 9 times and lowered it 0 times.
Revenue
Met or beat 3 of 3 periods (2 above, 1 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $1.7B–$1.8B (Jan 28, 2026) → reaffirmed $1.7B–$1.8B (Feb 17, 2026) → reaffirmed $1.7B–$1.8B (May 11, 2026) → raised $1.8B–$1.9B (Aug 6, 2026) → raised $1.9B–$1.9B (Nov 5, 2026) | — | to be reported | — |
| Q4 2025 | $298M (Feb 18, 2025) | $452M | above the range | +51.6% |
| FY2025 | $1.1B–$1.2B (Jan 8, 2025) → reaffirmed $1.1B–$1.2B (Feb 18, 2025) → raised $1.2B–$1.3B (May 6, 2025) → raised $1.3B–$1.4B (Aug 5, 2025) → raised $1.3B–$1.4B (Nov 3, 2025) | $1.4B | above the range | +4.4% |
| FY2024 | $935M–$1.0B (Aug 6, 2024) → raised $970M–$1.0B (Oct 31, 2024) | $1.0B | within the range | +2.0% |
Net income
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| Q4 2025 | $137M (Feb 18, 2025) | — | — | — |
Adjusted EBITDA
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $1.1B–$1.2B (Jan 28, 2026) → reaffirmed $1.1B–$1.2B (Feb 17, 2026) → reaffirmed $1.1B–$1.2B (May 11, 2026) → raised $1.2B–$1.3B (Aug 6, 2026) → raised $1.2B–$1.3B (Nov 5, 2026) | — | to be reported | — |
| FY2025 | $755M–$805M (Jan 8, 2025) → reaffirmed $755M–$805M (Feb 18, 2025) → raised $790M–$840M (May 6, 2025) → raised $865M–$915M (Aug 5, 2025) → raised $885M–$935M (Nov 3, 2025) | — | — | — |
| FY2024 | $555M–$615M (Aug 6, 2024) → raised $595M–$625M (Oct 31, 2024) | — | — | — |
Adjusted EPS
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $7.75–$8.25 (Jan 28, 2026) → reaffirmed $7.75–$8.25 (Feb 17, 2026) → reaffirmed $7.75–$8.25 (May 11, 2026) → raised $8.65–$9.00 (Aug 6, 2026) → raised $8.75–$9.05 (Nov 5, 2026) | — | to be reported | — |
| FY2025 | $4.95–$5.35 (Jan 8, 2025) → reaffirmed $4.95–$5.35 (Feb 18, 2025) → raised $5.30–$5.70 (May 6, 2025) → raised $6.00–$6.40 (Aug 5, 2025) → raised $6.10–$6.50 (Nov 3, 2025) | — | — | — |
| FY2024 | $3.65–$4.05 (Aug 6, 2024) → raised $4.00–$4.20 (Oct 31, 2024) | — | — | — |
The latest quarter
Halozyme Therapeutics, Q3 2026: revenue $493M (+39% year over year), operating margin 59.8%, net earnings $247M, operating cash flow $258M. The chart follows the revenue to costs, profit and cash.
Questions
Does Halozyme Therapeutics beat its guidance?
Halozyme Therapeutics gave guidance in 12 earnings releases on file since Aug 6, 2024. Of 3 guided periods since reported, it met or beat its own guidance 3 times (100%). Revenue: 3 of 3, on average +19.4% against the guided midpoint.
How often does Halozyme Therapeutics raise guidance?
Its earnings releases raised guidance 9 times and lowered it 0 times since Aug 6, 2024.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.